RADical response puts an exceptional responder in CHKmate: A synthetic lethal curative response to DNA-Damaging chemotherapy?

Guang Peng, Scott E. Woodman, Gordon Mills

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.

Original languageEnglish (US)
Pages (from-to)988-990
Number of pages3
JournalCancer Discovery
Volume4
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

irinotecan
Drug Therapy
DNA
Neoplasms
Genetic Therapy
Clinical Trials
Genome
Mutation
Therapeutics
Genes
Checkpoint Kinase 1

ASJC Scopus subject areas

  • Oncology

Cite this

RADical response puts an exceptional responder in CHKmate : A synthetic lethal curative response to DNA-Damaging chemotherapy? / Peng, Guang; Woodman, Scott E.; Mills, Gordon.

In: Cancer Discovery, Vol. 4, No. 9, 01.01.2014, p. 988-990.

Research output: Contribution to journalArticle

@article{fe15c03a34e641d0b4d7466bb5877c70,
title = "RADical response puts an exceptional responder in CHKmate: A synthetic lethal curative response to DNA-Damaging chemotherapy?",
abstract = "In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.",
author = "Guang Peng and Woodman, {Scott E.} and Gordon Mills",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/2159-8290.CD-14-0738",
language = "English (US)",
volume = "4",
pages = "988--990",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - RADical response puts an exceptional responder in CHKmate

T2 - A synthetic lethal curative response to DNA-Damaging chemotherapy?

AU - Peng, Guang

AU - Woodman, Scott E.

AU - Mills, Gordon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.

AB - In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.

UR - http://www.scopus.com/inward/record.url?scp=84906899772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906899772&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0738

DO - 10.1158/2159-8290.CD-14-0738

M3 - Article

C2 - 25185187

AN - SCOPUS:84906899772

VL - 4

SP - 988

EP - 990

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 9

ER -